ARC-T Cells Plus SPRX002
Master Protocol for the Phase 1 Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome, Including Long-term Safety Follow-up
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 24 patients (estimated)
- Sponsors
- Arcellx, Inc.
- Tags
- CAR T Cell, CD123
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1570
- NCT Identifier
- NCT05457010
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.